852062-08-9

Basic information

• Product Name: 4-Chloro-7-Methoxyquinoline-3-caroboxylic acid
• Synonyms: 4-Chloro-7-Methoxyquinoline-3-caroboxylic acid;4-Chloro-7-Methoxyquinoline-3-carboxylic acid
• CAS NO: 852062-08-9
• Molecular Formula: C11H8ClNO3
• Molecular Weight: 237.63912
• Mol File: 852062-08-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 389.2±37.0 °C(Predicted)
• Appearance: /
• Density: 1.438±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.58±0.30(Predicted)
• CAS DataBase Reference: 4-Chloro-7-Methoxyquinoline-3-caroboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-7-Methoxyquinoline-3-caroboxylic acid(852062-08-9)
• EPA Substance Registry System: 4-Chloro-7-Methoxyquinoline-3-caroboxylic acid(852062-08-9)

Safety Data

• Hazardous Substances Data: 852062-08-9(Hazardous Substances Data)

Usage

General Description

4-Chloro-7-Methoxyquinoline-3-carboxylic acid is a chemical compound with the molecular formula C11H8ClNO4. It is a quinoline derivative with a chloro substituent at the 4 position and a methoxy substituent at the 7 position. The presence of a carboxylic acid group at the 3 position gives it acidic properties. 4-Chloro-7-Methoxyquinoline-3-caroboxylic acid has potential applications in the field of medicinal chemistry, particularly as a building block for the synthesis of pharmaceutical drugs. Its structural features make it useful for the development of drug candidates targeting specific biological pathways. Additionally, it may also have utility as a fluorescent probe or chemical intermediate in research and industrial processes.

Upstream product

• 77156-85-5 Ethyl 4-chloro-7-methoxyquinoline-3-carboxylate 

Relevant articles and documents

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.